Stay current with the latest news on Blood Cancer United research programs, FDA approvals, research grants and awards, the Therapy Acceleration Program, Beat AML and other clinical research programs, and more.
News
FDA Approves New Treatment Option for Select Patients with Previously Untreated CLL, SLL
Blood Cancer United was at the forefront of funding research that advanced the understanding of the role of the BTK protein in the proliferation of se…
News
Blood Cancer United and Edward P. Evans Foundation Collaboration Advances Research for Patients With Myelodysplastic Syndromes
The collaboration includes a $2.5 million investment from both Blood Cancer United and the Edward P. Evans Foundation to support a five-year multidisc…
News
Nearly $7 Million in New Funding Accelerates Hairy Cell Leukemia Research
The Hairy Cell Leukemia Foundation and Blood Cancer United have extended their partnership to accelerate a cure and improve quality of life for patien…
News
Blood Cancer United Announces $7.5 Million Gift From Royalty Pharma to Expand Therapy Acceleration Program
Donation marks a new phase for Blood Cancer United’s venture philanthropy program, with returns reinvested to support future therapies
News
FDA Approves Treatment for Rare Blood Cancer Essential Thrombocythemia
The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (BESREMi®) for adults with essential thrombocythemia; the first …
News
FDA Approves First-of-its-Kind Treatment for Polycythemia Vera
In 2019, Blood Cancer United, in partnership with the MPN Research Foundation, funded a grant which expanded the scientific understanding related to h…
News
FDA Approves First-of-its-Kind Treatment for Multiple Myeloma
“We continue to be encouraged by the sustained progress being made in myeloma research and remain hopeful that advances like this will lead to better …
News
Beat AML® Study Provides New Data on 14-Day vs. 28-Day Venetoclax-Azacitidine Treatment in AML
Clinicians often reduce the duration of venetoclax because of side effects, but study finds 14-day schedule fell short in older patients with newly di…
News
The Harry T. Mangurian, Jr. Foundation Surpasses $25M in Support With New $4M Commitment
The Harry T. Mangurian, Jr. Foundation has made a new $4 million commitment to Blood Cancer United, bringing the foundation's total support to more th…
TAP Partner Allotera Therapeutics Closes $35 Million Financing to Advance Novel CAR-T Therapy for T-cell Cancers
Allotera Therapeutics partners with the Blood Cancer United Therapy Acceleration Program (TAP) to support development of its off-the-shelf CAR-T thera…
TAP Portfolio Highlights – EHA 2026
At the recent 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden, Blood Cancer United’s Therapy Acceleration Program (TAP) compa…
TAP Partner Solu Therapeutics Receives FDA Fast Track Designation
FDA grants Fast Track designation to STX-0712, an investigational treatment for patients with CMML.
